Background Mature progression-free survival (PFS) data from the phase III J-ALEX study
showed superiority for alectinib versus crizotinib [hazard ratio (HR) 0.37, 95% confidence …

Abstract Objectives The J-ALEX study compared the efficacy and safety of alectinib with
crizotinib in Japanese patients with advanced ALK-positive non-small-cell lung cancer …

LBA9008 Background: Alectinib, a TKI targeting ALK, has shown robust efficacy in crizotinib-
naïve/resistant ALK+ NSCLC. J-ALEX showed superiority of alectinib 300mg BID vs …

Background Alectinib, a highly selective inhibitor of anaplastic lymphoma kinase (ALK), has
shown systemic and central nervous system (CNS) efficacy in the treatment of ALK-positive …

Background The ALEX study demonstrated significantly improved progression-free survival
(PFS) with alectinib versus crizotinib in treatment-naive ALK-positive non-small-cell lung …

Objective To systematically evaluate the efficacy and safety of alectinib versus crizotinib in
the treatment of anaplastic lymphoma kinase (ALK) positive non-small-cell lung cancer …

Purpose The current study was carried out to compare the effectiveness and safety of
different ALK inhibitors in treating ALK+ NSCLC. Methods Progression‐free survival (PFS) …

9022 Background: The primary analysis of the J-ALEX (JapicCTI-132316) study for the ALK-
inhibitor naïve ALK+ NSCLC demonstrated superior progression-free survival (PFS) in …

9008 Background: ALC showed promising efficacy and tolerability in the phase I/II study (AF-
001JP). Here, we conducted the randomized open-label phase III trial (J-ALEX study …

9092 Background: The primary analysis of the J-ALEX (JapicCTI-132316) study for the ALK-
inhibitor naïve ALK+ NSCLC demonstrated superior progression-free survival (PFS) of ALC …